Literature DB >> 23745996

Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis.

L Cantarini1, O M Lucherini, A Vitale, L Sabadini, M G Brizi, B Frediani, I Muscari, M Galeazzi.   

Abstract

Although idiopathic recurrent acute pericarditis (IRAP) is generally presumed to derive from an autoimmune process, increasing interest is currently being devoted to autoinflammatory diseases, a group of disorders of the innate immune system caused by mutations of genes involved in the regulation or activation of the inflammatory response, without any apparent involvement of autoimmunity. The tumour necrosis factor receptor-1-associated periodic syndrome is the most common autosomal dominant autoinflammatory disorder and is caused by mutations in the TNFRSF1A gene encoding the 55-kD receptor for tumour necrosis factor-α. IRAP patients carrying TNFRSF1A gene mutations have been recently described. We report herein the first IRAP patients carrying the rare R104Q and D12ETNFRSF1A gene mutations, thus expanding the spectrum of tumour necrosis factor receptor-1-associated periodic syndrome mutations in IRAP patients.
© 2013 The Authors; Internal Medicine Journal © 2013 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23745996     DOI: 10.1111/imj.12163

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  7 in total

1.  The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy.

Authors:  Antonio Vitale; Donato Rigante; Orso Maria Lucherini; Anna De Palma; Ida Orlando; Stefano Gentileschi; Jurgen Sota; Antonella Simpatico; Claudia Fabiani; Mauro Galeazzi; Bruno Frediani; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2017-02-13       Impact factor: 3.397

Review 2.  Cardiovascular disease in patients with autoinflammatory syndromes.

Authors:  Rainer Hintenberger; Agnes Falkinger; Kathrin Danninger; Herwig Pieringer
Journal:  Rheumatol Int       Date:  2017-11-01       Impact factor: 2.631

Review 3.  Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Donato Rigante; Giuseppe Lopalco; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Giacomo Emmi; Luisa Costa; Elena Silvestri; Laura Andreozzi; Florenzo Iannone; Mauro Galeazzi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2014-06-17       Impact factor: 2.980

Review 4.  Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens.

Authors:  Marco Cattalini; Martina Soliani; Giuseppe Lopalco; Donato Rigante; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2016-05-25       Impact factor: 3.397

Review 5.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

Review 6.  Revisiting TNF Receptor-Associated Periodic Syndrome (TRAPS): Current Perspectives.

Authors:  Cornelia Cudrici; Natalie Deuitch; Ivona Aksentijevich
Journal:  Int J Mol Sci       Date:  2020-05-05       Impact factor: 5.923

7.  Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network.

Authors:  Carla Gaggiano; Donato Rigante; José Hernández-Rodríguez; Antonio Vitale; Maria Tarsia; Alessandra Soriano; Giuseppe Lopalco; Florenzo Iannone; Masen Abdel Jaber; Roberto Giacomelli; Ewa Wiȩsik-Szewczyk; Marco Cattalini; Micol Frassi; Matteo Piga; Gaafar Ragab; Jurgen Sota; Fiammetta Zunica; Alberto Floris; Vito Sabato; Mohamed Tharwat Hegazy; Olga Araújo; Laura Pelegrín; Alessandra Fabbiani; Alessandra Renieri; Salvatore Grosso; Claudia Fabiani; Bruno Frediani; Luca Cantarini
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-09-09       Impact factor: 5.346

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.